Business
Collaboration into identifying diagnosis of Autism
Collaboration into identifying diagnosis of Autism.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 9660G Oxford BioDynamics PLC 12 November 2018 \n\n12 November 2018\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nOxford BioDynamics enters into collaboration to identify EpiSwitch™ biomarkers for the diagnosis of Autism Spectrum Disorder (ASD)\n \n· Diagnosis of ASD is challenging, indicating the need for accurate diagnostic biomarkers.\n· Agreement signed with Casa Sollievo della Sofferenza, a recognised research and biomedical institution of national importance in Italy.\n \nOxford BioDynamics Plc announces that it has signed a collaboration agreement with Casa Sollievo della Sofferenza, a recognised research and biomedical institution of national importance in Italy, to identify EpiSwitch™ biomarkers for the blood-based diagnosis of Autism Spectrum Disorder (ASD).\n \nThe agreement between OBD and Casa Sollievo della Sofferenza aims to develop a diagnostic biomarker assay for ASD, using the EpiSwitch™ technology platform. Casa Sollievo della Sofferenza will supply blood samples from both autistic subjects and healthy controls. These will then be screened at high resolution for epigenetic changes, in the form of chromosome conformational signatures, by OBD using the EpiSwitch™ high throughput technology platform. In addition to identifying a potential diagnostic biomarker assay, OBD hopes to expand the epigenetic knowledge base for ASD, facilitating future research and pharmaceutical development into this spectrum of disorders.\n \nASD, which is thought to be caused by a complex interaction of genetic, epigenetic and environmental factors, represents a group of neurodevelopmental disorders, characterised by problems with social interaction and communication. It is estimated that approximately 1 in every 100 people in the UK has ASD. There is no cure for ASD, however speech and language therapy, occupational therapy and educational support provide great benefits for these patients. Earlier diagnosis would allow more timely intervention, improving the results of treatment and enhancing clinical outcomes.\n \nCurrently, diagnosis for ASD remains challenging due to broad ranging symptoms and differential progression and manifestation of the disorder. As the Epi...